An mRNA vaccine that targets several aspects of C. difficile’s ability to cause severe disease prevented major symptoms and death in mice.

H. pylori infections occur across the world due to exposure to saliva or stool in contaminated water or food. Learn how the ...

The US Department of Health and Human Services (HHS) last week announced funding for a project that will use artificial ...

Updated guidelines recommend fidaxomicin as the first-line agent for C difficile infection, but researchers found use in US ...

But when serious infection sets in, the most powerful antibiotics take a merciless approach, wiping out colonies of beneficial bacteria in the digestive tract and often prompting secondary health ...

New analyses extend data on beneficial effects of ibezapolstat on the gut microbiomeConfirmed ibezapolstat's favorable pharmacokinetics showing low systemic exposure and high colonic ...

In the period spanning 2017-2021, a mere 12 new antibiotics entered the market, with only one capable of targeting all the ...

Discover Merck's groundbreaking patent on genetic markers linked to enhanced C. difficile treatment responses. Learn how personalized therapy can improve patient outcomes.

Adults with three or more diarrheal stools (defined as liquid or unformed) per day or six or more diarrheal stools in a 36-hour period and a positive result for C. difficile toxin by enzyme ...

The patient's only antibiotic exposure was to trimethoprim ... the prevalence and virulence of this new strain of C. difficile and to determine if person-to-person transmission is now occurring ...

diff., a bacterium that can cause serious infections in the colon. Symptoms can range from mild diarrhea and stomach pain to significant colon damage, which can sometimes require surgery. “Antibiotics ...

But now, with bacteria evolving resistance to more and more antibiotics, phage therapy is drawing a second look from researchers—sometimes with a novel twist. Instead of simply using the phages ...